IHR1032-Tamoxifen citrate
TAMOXIFEN CITRATE(Nolvadex), >99 %
【英文同义名】:TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex®
【中文同义名】:塔莫西酚
订购信息:(原装进口,常备现货)
| 品 牌 | 产品名称 | 产品货号 | 规 格 | 目录价(元) |
| Gene Operation | TAMOXIFEN CITRATE(Nolvadex) (estrogen receptor modulator) | IHR1032-0050MG | 50MG | 369 |
| IHR1032-0100MG | 100MG | 719 |
| IHR1032-0500MG | 500MG | 2139 |
产品描述
Tamoxifen citrate (同义名: TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex®
) 是Tamoxifen的枸橼酸盐,是选择性Estrogen receptor(ER)(雌***受体)调控剂。Tamoxifen在乳腺中表现出拮抗功能,而在其它组织,如子宫内膜中是一种激动剂。Tamoxifen抑制SR31747与重组mSI和his的结合,IC50分别为1.9 nM和3.6 nM。Tamoxifen选择性抑制哺乳动物SI细胞中的甾醇生成[1]。Tamoxifen提高乳腺癌中VEGF mRNA表达,在体内实验中,却降低MCF-7移植瘤小鼠中细胞外VEGF水平。Tamoxifen辅助治疗雌***依赖的乳腺癌,可以阻止肿瘤细胞转移,并提高病人存活[2]。Tamoxifen还可以降低女性血清中LDL胆固醇,已经用于女性乳腺癌的治疗。
靶点
化学特性
| Cas No.: 54965-24-1 | 分子量: 563.64 |
| 分子式: C26H29NO·C6H8O7 | 纯度: >99% |
| 同义名: TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex® |
| 化学名:(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate |
外观: 白色结晶粉末 |
| 溶解: 溶于DMSO(up to 100 mg/mL) |
| 保存:3年 -20℃ 粉末 |
储存液配制
| 储存液 (1 ml DMSO体系) | 1 mM | 5 mM | 10 mM | 25 mM | 50 mM | 100 mM |
| 质量(mg) | 0.5636 | 2.8182 | 5.6364 | 14.0910 | 28.1820 | 56.3640 |
结构式

使用浓度(仅作参考)
Tamoxifen citrate的具体使用浓度请参考相关文献,并根据自身实验条件(如实验目的,细胞种类,培养特性等)进行摸索和优化。
参考文献
[1] Clarke M, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 351(9114):1451-67 (1998).
[2] Johnson MD, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl ***, a novel active metabolite of ***. Breast Cancer Research and Treatment 85(2):151-9 (2004).
[3] Gottardis MM, et al. Contrasting actions of *** on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48(4):812-5 (1988).
[4] Love RR, et al. Effects of *** on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326(13):852-6 (1992).
[5] Guetta V, et al. Effects of the antiestrogen *** on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 76(14):1072-3 (1995).
[6] Thomas P, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 146(2):624-32 (2005).
[7] OBrian CA, et al. Inhibition of protein kinase C by ***. Cancer Res. 45(6):2462-5 (1985).